Autologous peripheral blood stem cell transplantation following heart transplantation for primary systemic amyloidosis.
A 47 years old woman was admitted with severe congestive heart failure. Cardiac echography showed increased intra-ventricular septum thickness, and there was a serum Ig G lambda monoclonal component. Cardiac biopsies confirmed diffuse amyloidosis of Al type. To avoid cardiac toxicity of chemotherapy, the patient received first a heart transplantation (HT), followed six months later by melphalan 200 mg/m(2) and autologous peripheral blood stem cell support (PBSCT). This case suggests that such strategy is feasible with a favorable outcome, and HT may be an appropriate procedure for some patients with Al amyloidosis who meet the criteria for PBSCT.
Mohty
M
M
Hematology and Medical Oncology Department, CHU de Montpellier, Hôpital Lapeyronie, 34295 Montpellier Cedex 05, France.
Albat
B
B
Fegueux
N
N
Rossi
J F
JF
D000686:Amyloidosis / Q000628:therapy*; D017809:Fatal Outcome; D005260:Female; D006333:Heart Failure / Q000209:etiology / Q000628:therapy; D016027:Heart Transplantation; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D014182:Transplantation, Autologous
D008558:Melphalan